Gliotransmission: A Novel Target for the Development of Antiseizure Drugs.
ATP
chronic epilepsy models
drug-resistant epilepsy
gliotransmission
glutamatergic receptors
pharmacological targets
purinergic receptors
Journal
The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry
ISSN: 1089-4098
Titre abrégé: Neuroscientist
Pays: United States
ID NLM: 9504819
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
25
1
2020
medline:
4
6
2021
entrez:
25
1
2020
Statut:
ppublish
Résumé
For more than a century, epilepsy has remained an incapacitating neurological disorder with a high incidence worldwide. Mesial temporal lobe epilepsy (TLE) is a common type of epilepsy without an effective pharmacological treatment. An increase in excitability and hypersynchrony of electrical neuronal activity during development are typically associated with an excitatory/inhibitory imbalance in the neuronal network. Astrocytes release gliotransmitters, which can regulate neuronal excitability and synaptic transmission; therefore, the classical neurocentric vision of the cellular basis of epileptogenesis has begun to change. Growing evidence suggests that the key contribution of astrocyte-to-neuron signaling in the mechanisms underlies the initiation, propagation, and recurrence of seizure activity. The aim of this review was to summarize current evidence obtained from experimental models that suggest how alterations in astroglial modulation of synaptic transmission and neuronal activity contribute to the development of this brain disease. In this article, we will summarize the main pharmacological, Ca
Identifiants
pubmed: 31976817
doi: 10.1177/1073858420901474
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM